Company intelligence / Profile preview

Vertero Therapeutics

Woburn, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Lead candidate VT-5006, a first-in-class oral small molecule targeting pathological processes in the gut, shows strong safety and efficacy signals in preclinical studies for Parkinson’s disease and is scheduled to enter Phase 1 in Q4 2025. The pipeline also includes an early-stage asset addressing bile acid dysregulation for an undisclosed indication.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

5 assets

AB-2004

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Vertero Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vertero Therapeutics.

Explore the full profile